[1] Araujo AR,Rosso N,Bedogni G,et al.Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis:What we need in the future. Liver Int,2018,38(Suppl 1):47-51. [2] Perumpail BJ,Khan MA,Yoo ER,et al.Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol,2017,23(47):8263-8276. [3] Terrault NA,Lok ASF,McMahon BJ,et al. Update on prevention,diagnosis,and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Hepatology,2018,67(4):1560-1599. [4] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67(2):370-398. [5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-ⅩⅩⅢ. [6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会. 非酒精性脂肪性肝病防治指南(2018年版). 实用肝脏病杂志,2018,21(2):177-186. [7] Marengo A,Jouness RI,Bugianesi E,et al.Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis,2016,20(2):313-324. [8] Tada T,Kumada T,Toyoda H,et al.Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun,2017,1(9):899-910. [9] Sasso M,Beaugrand M,de Ledinghen V,et al. Controlled attenuation parameter(CAP):a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol,2010,36(11):1825-1835. [10] Non-alcoholic Fatty Liver Disease Study Group,Lonardo A,Bellentani S,et al. Epidemiological modifiers of non-alcoholic fatty liver disease:focus on high-risk groups. Dig Liver Dis,2015,47(12):997-1006. [11] De Lédinghen V,Hiriart JB,Vergniol J,et al.Controlled attenuation parameter(CAP) with the XL probe of the Fibroscan<sup>®</sup>: a comparative study with the M probe and liver biopsy. Dig Dis Sci,2017,62(9):2569-2577. [12] Petta S,Wong VW,Cammà C,et al.Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology,2017,65(4):1145-1155. [13] Andrade P,Rodrigues S,Rodrigues-Pinto E,et al.Diagnostic accuracy of controlled attenuation parameter for detecting hepatic steatosis in patients with chronic liver disease. GE Port J Gastroenterol,2017,24(4):161-168. [14] Kaya E,Demir D,Alahdab YO,et al.Prevalence of hepatic steatosis in apparently healthy medical students:a transient elastography study on the basis of a controlled attenuation parameter. Eur J Gastroenterol Hepatol,2016,28(11):1264-1267. [15] Chen J,Wu D,Wang M,et al.Controlled attenuation parameter for the detection of hepatic steatosis in patients with chronic hepatitis B. Infect Dis (Lond),2016,48(9):670-675. [16] Karlas T,Petroff D,Sasso M,et al.Individual patient data meta-analysis of controlled attenuation parameter(CAP) technology for assessing steatosis. J Hepatol,2017,66(5):1022-1030. [17] De Lédinghen V,Vergniol J,Capdepont M,et al.Controlled attenuation paramete(CAP) for the diagnosis of steatosis:a prospective study of 5323 examinations. J Hepatol,2014,60(5):1026-1031. |